"Survey Finds Increased Caloric Intake After Discontinuing Weight Loss Medication"

A Deutsche Bank survey found that calorie consumption declines when patients take GLP-1 medications like Novo Nordisk's Ozempic or Wegovy, but once the medication is stopped, calorie intake rises again, sometimes even surpassing pre-treatment levels. The survey also revealed that interest in weight loss programs may be peaking, which could be a good time for investors to hold food and beverage stocks. Additionally, the survey results align with the understanding that appetite can return strongly after stopping GLP-1 therapy, highlighting the long-term implications of anti-obesity medications on the food and beverage industry.